TopoTarget: Difference between revisions

Revision as of 16:12, 9 February 2025

TopoTarget

Logo of TopoTarget

TopoTarget was a biotechnology company focused on the development of cancer therapies. Founded in 2000, the company was based in Copenhagen, Denmark. TopoTarget specialized in the research and development of histone deacetylase inhibitors (HDAC inhibitors) and other targeted therapies for the treatment of cancer.

History

TopoTarget was established by a group of scientists and entrepreneurs with expertise in cancer research and drug development. The company aimed to develop innovative treatments that target specific mechanisms involved in cancer progression. In 2004, TopoTarget was listed on the Copenhagen Stock Exchange.

Research and Development

TopoTarget's research primarily focused on HDAC inhibitors, which are compounds that interfere with the function of histone deacetylases. These enzymes play a crucial role in the regulation of gene expression by modifying the chromatin structure. By inhibiting HDACs, TopoTarget aimed to reactivate tumor suppressor genes and induce apoptosis in cancer cells.

Hsp90, a protein targeted by some of TopoTarget's research

One of the company's lead compounds was belinostat, an HDAC inhibitor that showed promise in the treatment of various cancers, including peripheral T-cell lymphoma. Belinostat was developed in collaboration with other pharmaceutical companies and underwent several clinical trials.

Acquisition

In 2014, TopoTarget merged with BioAlliance Pharma, a French biotechnology company, to form Onxeo. This merger was aimed at creating a stronger entity with a broader portfolio of oncology products and a more extensive pipeline of drug candidates.

Related pages

References

@@ Line 1: / Line 1: @@
-'''TopoTarget''' is a biopharmaceutical company that specializes in the development of therapeutics for the treatment of cancer. The company focuses on the discovery and development of novel drugs that target topoisomerases, enzymes critical for the process of [[DNA replication]] and [[cell division]]. By inhibiting these enzymes, TopoTarget aims to develop treatments that can effectively combat various forms of [[cancer]] by preventing cancer cells from proliferating.
+== TopoTarget ==
-==History==
+[[File:TopoTarget_logo.jpg|thumb|Logo of TopoTarget]]
-TopoTarget was founded with the goal of leveraging cutting-edge research in the field of [[molecular biology]] and [[oncology]] to develop innovative cancer therapies. Over the years, the company has established itself as a leader in the development of topoisomerase inhibitors, with a pipeline of drug candidates in various stages of clinical development.
-==Research and Development==
+'''TopoTarget''' was a [[biotechnology]] company focused on the development of [[cancer]] therapies. Founded in 2000, the company was based in [[Copenhagen]], [[Denmark]]. TopoTarget specialized in the research and development of [[histone deacetylase inhibitors]] (HDAC inhibitors) and other [[targeted therapies]] for the treatment of [[cancer]].
-The research and development efforts at TopoTarget are centered around the identification and validation of novel drug targets within the topoisomerase enzyme family. The company employs a range of [[biotechnology]] and [[pharmacology]] techniques to design and test compounds that can selectively inhibit these enzymes. The ultimate goal is to develop drugs that are both effective against cancer cells and have a favorable safety profile for patients.
-==Product Pipeline==
+== History ==
-TopoTarget's product pipeline includes several promising drug candidates that are in different phases of clinical trials. These candidates are being tested for efficacy in treating a variety of cancers, including [[breast cancer]], [[lung cancer]], and [[leukemia]]. The company's strategy involves conducting rigorous clinical trials to demonstrate the safety and effectiveness of its drug candidates before seeking regulatory approval for commercialization.
-==Collaborations and Partnerships==
+TopoTarget was established by a group of scientists and entrepreneurs with expertise in cancer research and drug development. The company aimed to develop innovative treatments that target specific mechanisms involved in cancer progression. In 2004, TopoTarget was listed on the [[Copenhagen Stock Exchange]].
-Recognizing the importance of collaboration in the field of drug development, TopoTarget has established partnerships with other biopharmaceutical companies, academic institutions, and research organizations. These collaborations aim to accelerate the development of its drug candidates by leveraging external expertise and resources.
-==Challenges and Opportunities==
+== Research and Development ==
-Like many companies in the biopharmaceutical industry, TopoTarget faces challenges such as the high cost of drug development, regulatory hurdles, and the need for continuous innovation. However, the company's focus on targeting a critical mechanism of cancer cell proliferation presents significant opportunities for developing breakthrough therapies that can improve the lives of patients with cancer.
-==Conclusion==
+TopoTarget's research primarily focused on HDAC inhibitors, which are compounds that interfere with the function of [[histone deacetylases]]. These enzymes play a crucial role in the regulation of [[gene expression]] by modifying the [[chromatin]] structure. By inhibiting HDACs, TopoTarget aimed to reactivate [[tumor suppressor genes]] and induce [[apoptosis]] in cancer cells.
-TopoTarget represents a key player in the field of cancer therapeutics, with a focus on developing drugs that inhibit topoisomerases. Through its dedicated research and development efforts, the company aims to bring new hope to patients suffering from cancer by providing innovative treatments that can effectively combat this devastating disease.
-[[Category:Biopharmaceutical companies]]
+[[File:Hsp90.jpg|thumb|Hsp90, a protein targeted by some of TopoTarget's research]]
-[[Category:Cancer research]]
-[[Category:Pharmacology]]
-{{cancer-stub}}
+One of the company's lead compounds was [[belinostat]], an HDAC inhibitor that showed promise in the treatment of various cancers, including [[peripheral T-cell lymphoma]]. Belinostat was developed in collaboration with other pharmaceutical companies and underwent several clinical trials.
+== Acquisition ==
+In 2014, TopoTarget merged with [[BioAlliance Pharma]], a French biotechnology company, to form [[Onxeo]]. This merger was aimed at creating a stronger entity with a broader portfolio of oncology products and a more extensive pipeline of drug candidates.
+== Related pages ==
+* [[Histone deacetylase inhibitor]]
+* [[Cancer treatment]]
+* [[Onxeo]]
+== References ==
+{{Reflist}}
+[[Category:Biotechnology companies]]
+[[Category:Companies established in 2000]]
+[[Category:Companies based in Copenhagen]]